Liver-First Heart-Liver Transplant Lowers Rejection Risk in Highly Sensitized Patients

For highly sensitized patients awaiting a combined heart-liver transplant, the simple question of which organ goes in first has become clinically important. Surgeons and transplant teams are now testing a “liver-first” approach because the liver’s special immune-tolerant properties can soak up harmful antibodies that would otherwise attack the new heart. In practice, transplanting the liver first can dramatically blunt the immune response against the heart. Recent clinical reports show dramatic results: for example, one center found that in seven patients with very high antibody levels, the liver-first sequence drove antibody levels down and none of those patients had acute heart rejection over four years.

Why It Matters

Being sensitized means a patient has high levels of pre-formed antibodies against human leukocyte antigens (HLA) are the molecular “flags” on donor organs. Sensitization often comes from past events like blood transfusions, prior transplants, pregnancies or infections. Doctors measure this with a “panel reactive antibody” (PRA) score. A PRA of 80–90% means the patient’s antibodies will react to most donor organs. This makes it extremely hard to find a match. For a heart transplant, these antibodies pose a high risk: if they recognize the new heart, they can attack it within hours or days in what’s called antibody-mediated rejection. This can cause sudden graft failure, emergency surgery or even death. The liver occupies a special role in transplant immunology. It is often called an “immune-privileged” organ because it naturally tolerates foreign tissue better than most organs. Part of the reason is its large size, high blood flow and unique immune cells (like Kupffer cells) that can absorb or neutralize antibodies. Doctors have long noted that when a liver is transplanted along with another organ (such as a kidney or heart), the liver often shields the other organ from rejection. By putting the liver in first, transplant teams take advantage of this effect. The new liver can act like a sponge for the patient’s circulating antibodies and can also send signals that tone down the immune attack. In practical terms, this means the heart that comes next has a much better chance to survive without being hit by the full antibody storm. If more highly sensitized patients could receive the combination of heart and liver transplants through this low rate of organ rejection, things would definitely change. There are many people who are otherwise eligible for heart transplant but because of sensitivity issues cannot undergo the procedure alone but through a liver-heart transplant would be eligible to receive the transplant surgery. This method will definitely require changes in the allocation criteria followed by various hospitals and transplant centers. On the other hand, there are also some problems with the liver-first method as it requires a complicated surgery and post-surgery care.

Who It Affects

This is significant especially among those that require transplantation of the heart and the liver simultaneously while being highly sensitized. Clinically, this applies to young or middle-age patients with a history of medical conditions over time. These may be individuals born with congenital heart disease, and have undergone several operations or received numerous blood transfusions, thus becoming highly sensitized. Over time, conditions such as heart failure with congestion can lead to liver dysfunction, and thus a need for both organs. Other examples may include genetic disorders such as hemochromatosis (iron overload) and transthyretin amyloidosis, in which case failure occurs in both the heart and the liver. Transplant surgeons and hepatologists are on the front lines of this approach. They must evaluate each patient’s antibody profile and coordinate the tricky logistics of a two-organ operation. Teams of specialists such as heart surgeons, liver surgeons, anesthesiologists and perfusionists must work in sync. In a liver-first operation, the heart transplant immediately follows the liver transplant in the same operating session. Intensive care teams and transplant nurses must then manage the patient through recovery from two major surgeries. Every step needs careful planning: from the timing of organ retrieval to anesthesia adjustments between the liver and heart phases.

Insurers and hospitals are well aware of this trend. Combined transplants are expensive procedures. Two organs, two operations and increased time spent in ICU all lead to increased costs and complexities. Hospital managers and insurance companies will be interested in proof that these additional complications will be compensated. If the liver-first procedure dramatically decreases the risk of rejection in these people, it may result in decreased emergencies and reduced total length of hospitalization of these patients. However, one should consider the increased cost of surgery associated with it. Finally, organ transplantation bodies and ethical committees will be concerned. They will have to find out how to incorporate the new group of recipients into the existing list.

Families and caregivers are affected too. The decision for a liver-first transplant usually comes after years of waiting and medical ups-and-downs. In cases where this option is offered by the doctor, patients and their families have to undergo adequate counseling. They will be interested in learning all details concerning how it differs from the regular procedure: that it is a bit more complicated and lengthy but is likely to be the only solution that will ensure good health of the heart. Survival rates, risk factors, and duration of the procedure will also be discussed. It is important to discuss the possible complications and lack of experience with the treatment.

What Changes

• Clinical selection expands. More highly sensitized patients who previously had almost no heart transplant options may now be considered for combined heart-liver transplant. For example, a patient with a 90% PRA (meaning antibodies against 90% of donor hearts) who might never get a matched heart alone could be listed for a dual procedure. Transplant teams will need clear criteria to pick patients who stand to benefit most. They may use advanced antibody testing (like flow crossmatches or detailed HLA assays) and detailed health assessments to decide. The goal is to identify those whose antibody profiles can be neutralized by the liver so they can survive the transplant.
• Surgical planning becomes more coordinated. Operating room teams must now sequence the operation so the liver is implanted first. This changes the logistics entirely: the donor liver and heart must come from the same donor, and timing of organ recovery is critical. In practice, the patient first undergoes liver transplant, then is stabilized, and then goes straight to heart transplant on bypass. Anesthesia and perfusion teams must manage this long, staged process, keeping the patient stable between surgeries. Surgical coordinators will have to arrange for two specialized teams and make sure both organs are prepped and preserved correctly. Organ preservation solutions, transportation and backup plans all must be adjusted for the liver-first order.
• Post-operative care and monitoring adapt. After a typical heart transplant, doctors often use aggressive measures like plasmapheresis, IVIG, or extra immunosuppressive drugs to immediately combat any donor-specific antibodies. With the liver first approach, the initial antibody levels drop sharply, so the team may dial back those early anti-antibody treatments for the heart. However, careful monitoring remains crucial. Patients will have biopsies of both the liver and heart at planned intervals, and frequent blood tests to watch for any late antibody rebound or organ issues. The overall immunosuppression regimen might also be adjusted: for instance, the team might start with standard liver-transplant anti-rejection drugs (like tacrolimus) and then adapt as the heart graft settles in. Teams must be ready to respond if antibodies rise again, even months later.
• Policy and ethics discussions intensify. Transplant authorities and ethics boards are rethinking allocation rules. If it becomes clear that liver-first transplants save lives for highly sensitized patients, some experts will argue these cases deserve high priority. Others worry about fairness: using two organs for one person could disadvantage others on the waiting list. These concerns tie into broader equity debates in organ allocation. Policymakers may need to establish guidelines on who qualifies for combined transplant listing. They might, for example, require a defined level of antibody sensitization or liver disease before approving a two-organ listing. Data collection will be key: outcome registries must track survival and graft function in liver-first cases versus traditional cases to inform future policy.
• On the ground, the liver-first strategy also changes how care teams talk to patients. In clinic and during consent, doctors must explain the rationale clearly and kindly. Patients need to know that this surgery is more complex and carries higher immediate risks (such as bleeding or infection) because it involves two major operations. At the same time, they should understand that for some, it offers the best chance at a functioning heart. Patients and families will want honest answers about survival odds, the chance of rejection, and the recovery timeline. They should also discuss alternatives—such as heart-alone transplant with experimental antibody treatments or staying on medical therapy—so they can make an informed choice.

Finally, communication matters. Patients and families deserve clear explanations of why a liver-first operation might be the best option, and what recovery will involve. Educational materials, counseling sessions and support groups can help them understand the process. Clinicians should give realistic timelines (for example, how long the hospital stay and rehab might be) and discuss possible side effects of medications. It’s also helpful to share success stories from other patients (anonymously) or to connect new patients with veterans of dual transplant for peer support. Overall, the tone should be hopeful but grounded: the liver-first approach opens new possibilities, but it also comes with uncertainties.

Sequencing in multi-organ transplantation is clearly a critical detail that can change lives. For highly sensitized patients with both heart and liver failure, placing the liver first has already turned once-impossible cases into real successes at a few centers. This means potentially better survival for individuals and new options in the transplant system. At the same time, it adds layers of complexity in surgery, aftercare and policy. Medical teams, hospitals and policymakers will need to collaborate closely to integrate this approach thoughtfully. In the end, the liver-first strategy is a promising example of how insights in immunology and surgical technique can open doors for patients who had very few. It also highlights how much there still is to learn about harnessing the immune system to save lives.

References

1. Daly RC, Topilsky Y, Joyce L, Hasin T, Gandhi M, Rosen C, et al. Combined heart and liver transplantation: protection of the cardiac graft from antibody rejection by initial liver implantation. Transplantation. 2013;95(2):e2-e4. Available from: PubMed
2. Taner T, Biggins SW, Cummins N, et al. Summary of a Consensus Conference on the Management of Highly Sensitized Multiorgan Transplant Candidates. Mayo Clinic Proceedings. 2025;100(4):700-711. Available from: Full text
3. Sharma P, Arora A. Basic Understanding of Liver Transplant Immunology. Journal of Clinical and Experimental Hepatology. 2023;13(6):1091-1102. Available from: PMC
4. Health Resources and Services Administration. CPRA Calculator. Organ Procurement and Transplantation Network, HRSA. 2025. Available from: HRSA